Immunization with P10 Peptide Increases Specific Immunity and Protects Immunosuppressed BALB/c Mice Infected with Virulent Yeasts of Paracoccidioides brasiliensis Academic Article


  • Mycopathologia


  • Paracoccidioidomycosis is a systemic granulomatous disease caused by Paracoccidioides spp. A peptide from the major diagnostic antigen gp43, named P10, induces a T-CD4+ helper-1 immune response in mice and protects against intratracheal challenge with virulent P. brasiliensis. Previously, we evaluated the efficacy of the P10 peptide alone or combined with antifungal drugs in mice immunosuppressed and infected with virulent isolate of P. brasiliensis. In the present work, our data suggest that P10 immunization leads to an effective cellular immune response associated with an enhanced T cell proliferative response. P10-stimulated splenocytes increased nitric oxide (NO) production and induced high levels of IFN-γ, IL-1β and IL-12. Furthermore, significantly increased concentrations of pro-inflammatory cytokines were also observed in lung homogenates of immunized mice. P10 immunization was followed by minimal fibrosis in response to infection. Combined with antifungal drugs, P10 immunization most significantly improved survival of anergic infected mice. Administration of either itraconazole or sulfamethoxazole/trimethoprim together with P10 immunization resulted in 100 % survival up to 200 days post-infection, whereas untreated mice died within 80 days. Hence, our data show that P10 immunization promotes a strong specific immune response even in immunocompromised hosts and thus P10 treatment represents a powerful adjuvant therapy to chemotherapy.

publication date

  • 2014-1-1


  • 178


  • Cellular Immunity
  • Cytokines
  • Drug Therapy
  • Fibrosis
  • Immunity
  • Immunization
  • Immunocompromised Host
  • Infection
  • Interleukin-1
  • Interleukin-12
  • Itraconazole
  • Lung
  • Nitric Oxide
  • Paracoccidioides
  • Paracoccidioides brasiliensis
  • Paracoccidioidomycosis
  • Peptides
  • Pharmaceutical Preparations
  • Sulfamethoxazole Drug Combination Trimethoprim
  • T-Lymphocytes
  • T-lymphocytes
  • Therapeutics
  • Yeasts
  • adjuvants
  • antifungal agents
  • antigens
  • cell-mediated immunity
  • cytokines
  • drug therapy
  • fibrosis
  • gp43 tumor-associated antigen
  • immune response
  • immunity
  • immunization
  • immunocompromised population
  • infection
  • interleukin-1
  • interleukin-12
  • itraconazole
  • lungs
  • mice
  • nitric oxide
  • peptides
  • splenocytes
  • sulfamethoxazole
  • therapeutics
  • trimethoprim
  • yeasts

International Standard Serial Number (ISSN)

  • 0301-486X

number of pages

  • 12

start page

  • 177

end page

  • 188